Given that serum TARC and IL-22 levels correlated positively with VAS more strongly than with serum IgE level, serum TARC and IL-22 levels may be excellent parameters for assessing the efficacy of treating AD with dupilumab. The gene discussed is IL22; the disease is Alzheimer disease.